Publication Cover
Hemoglobin
international journal for hemoglobin research
Volume 46, 2022 - Issue 2
178
Views
0
CrossRef citations to date
0
Altmetric
Research Articles

The Long-Term Efficacy of Deferiprone in Thalassemia Patients With Iron Overload: Real-World Data from the Registry Database

, ORCID Icon, , , , ORCID Icon, , , , , & ORCID Icon show all
Pages 75-80 | Received 18 Jan 2022, Accepted 01 Mar 2022, Published online: 18 Aug 2022
 

Abstract

Deferiprone (DFP) is an oral iron-chelating agent that is widely used in thalassemia patients with iron overload. This study aimed to investigate the long-term efficacy of DFP monotherapy on serum ferritin (SF) and adverse events. All thalassemia patients aged 15 years or older who received DFP monotherapy were identified from the thalassemia registry database between November 2008 and October 2019. After treatment, patients who achieved a target SF level, defined as <1000.0 ng/mL in transfusion-dependent thalassemia (TDT) and <800.0 ng/mL in non-TDT (NTDT) for two consecutive visits, were categorized as the achievable group. We used multivariate analysis to identify factors that contribute to differences between groups. One hundred and five patients were enrolled in the study with a median age of 28 (19–41) years and median initial SF level of 1399.0 (1141.0–2169.0) ng/mL. Of these, 61.0% carried Hb E (HBB: c.79G>A)/β-thalassemia (β-thal) and 60.0% were TDT patients. The median DFP dose was 63 (47–73) mg/kg/d and the median follow-up duration of treatment was 36 (20–54) months. A total of 58 (55.24%) patients were in the achievable group. The initial SF level <1350.0 ng/mL was significantly associated with achieving a targeted SF level (p = 0.002). Ten adverse events resulted in withholding DFP. The most common was gastrointestinal irritation in four patients and three patients with agranulocytosis. In conclusion, DFP is an effective iron chelator in thalassemia patients. Slightly more than half the patients (55.0%) achieved a target SF level. Lower SF levels at the beginning were an important factor.

Acknowledgments

We would like to thank Ms. Antika Wongthanee, Former Head of Analytical & Statistical Data Unit, Research Institute for Health Sciences, Chiang Mai University, Chiang Mai, Thailand, for her suggestions regarding the statistical analyses in this study. The authors would also like to express their gratitude to Dr. Yotsapon Thewjitcharoen, Theptarin Hospital, Bangkok, Thailand, for his generous advice and to Dr. Tinapa Himathongkam and for English language editing.

Disclosure statement

The authors report no conflicts of interest. The authors alone are responsible for the content and writing of this article.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.